Glioblastomas are the most common and most malignant glial tumors of the brain. Molecular studies (1,2) have identified a variety of genetic alterations in glioblastomas that result in the inactivation of cell cycle regulatory pathways and in the activation of intracellular signaling pathways such as those that involve the mitogen-activated protein kinase and the phosphatidylinositol 3-kinase (PI3K) cascades. In glioblastomas, activation of the PI3K signaling pathway is frequently accomplished by amplification, genetic rearrangement, and/or overexpression of growth factor receptor genes such as the epidermal growth factor receptor (EGFR) gene (2) . Furthermore, approximately one-third of glioblastomas carry mutations in the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene, whose gene product dephosphorylates phosphatidylinositol-(3,4,5)-triphosphate and thereby inhibits the PI3K-dependent activation of protein kinase B/Akt signaling (3). Akt activation has been shown to be important for the development of glioblastomas in different model systems (4, 5) , and phosphorylated (i.e., activated) Akt proteins have been detected in the majority of human glioblastomas (4, 6 . Human brain and tumor tissue samples were selected from the archives of the Department of Neuropathology, HeinrichHeine-University, and investigated as approved by the local institutional review board at Heinrich-Heine-University. DNA and RNA were extracted as described (8) .
All tumors and cell lines were analyzed for CTMP coding region mutations (GenBank accession No. NM_176853) by using single-strand conformation polymorphism analysis and DNA sequencing (8, 9) , and for homozygous deletion of CTMP by using duplex polymerase chain reaction (PCR) for the simultaneous amplification of fragments from CTMP and the reference gene adenine phosphoribosyltransferase (APRT; GenBank accession No. NM_000485) (8, 10) . None of the tumors or cell lines had somatic mutations in CTMP or had a homozygous deletion of CTMP. Peripheral blood samples were available from 57 of the 93 patients. These samples were subjected to loss of heterozygosity analysis at the microsatellite loci D1S2344 and D1S305, which map proximal and distal to CTMP at 1q21, respectively. None of the samples showed allelic loss.
We next assessed the CTMP mRNA levels in the 93 glioblastomas by realtime reverse transcription-PCR using primers binding to sequences shared by transcript variants 1 and 2 (GenBank accession Nos. NM_053055 and NM_176853). CTMP mRNA levels were normalized to the housekeeping gene ADP-ribosylation factor 1 (ARF1; GenBank accession No. NM_001658) and were compared with the normalized CTMP mRNA levels in non-neoplastic brain tissue samples obtained from an individual at autopsy or from patients undergoing surgery for chronic epilepsy or traumatic brain injury. Compared with those in non-neoplastic brain tissue, CTMP mRNA levels were reduced by at least 50% in 37 of 93 (40%) glioblastomas and in six of nine (67%) glioma cell lines (Figs. 1, A, and 2). To determine whether methylation differences in the CTMP promoter were responsible for the reduced mRNA expression, we selected 15 glioblastomas (10 tumors with CTMP mRNA levels reduced by Ն50% and five tumors with CTMP mRNA levels of Ն60% relative to nonneoplastic brain tissue), the nine cell lines, and non-neoplastic brain tissue samples from four different individuals for methylation analysis by sequencing the CTMP 5Ј-CpG island after sodium bisulfite modification of the DNA (10). For each sample, the genomic CTMP sequence from nucleotides Ϫ525 to 233 (GenBank accession No. AJ313515) was amplified in three fragments, each of which was cloned into pCR 2.1 vectors (Invitrogen, Carlsbad, CA). At least five clones of each fragment were sequenced to determine the methylation status. Hypermethylation (i.e., methylation of the majority of the 67 investigated CpG sites per sample) was observed in eight of 10 glioblastomas and in all cell lines with reduced CTMP mRNA levels (Figs. 1, B, and 2, A) . By contrast, hypermethylation was observed neither in the non-neoplastic brain samples nor in the tumors and cell lines with normal CTMP mRNA levels (Fig. 2, A) . To assess whether hypermethylation was responsible for the decreased mRNA expression, we treated the cell lines A172 and T98G, which were positive and negative for CTMP promoter hypermethylation, respectively, with the demethylating agent 5-aza-2Ј-deoxycytidine, the histone deacetylase inhibitor trichostatin A, or a combination of both. Relative to untreated A172 cells, CTMP mRNA expression increased in A172 cells treated with either drug (data not shown) or the combination (Fig. 1, D) . Furthermore, the treatment of A172 cells with the combination of 5-aza-2Ј-deoxycytidine and trichostatin A resulted in a partial demethylation of the hypermethylated CTMP CpG island (Fig. 2, A) . CTMP mRNA expression was unaltered in T98G cells after treatment with either drug alone (data not shown) or the combination (Fig. 1, D) .
To screen all 93 glioblastomas for CTMP hypermethylation, we digested tumor DNA with the methylationsensitive restriction enzyme HpaII, and used PCR to amplify eight different HpaII site-containing fragments from the CTMP CpG island (Figs. 1, C, and 2 , B). PCR conditions were optimized for each fragment by using DNA samples that had been analyzed by sequencing sodium bisulfite-modified DNA. HpaII restriction analysis revealed CTMP hypermethylation (i.e., methylation of at least four of eight HpaII site-containing fragments) in 29 of 37 (78%) glioblastomas with reduced CTMP mRNA levels and in two of 56 (4%) glioblas- Fig. 1. A tomas with normal CTMP mRNA levels (Fig. 2, B) . The relationship between CTMP hypermethylation and reduced mRNA expression was statistically significant (PϽ.001, two-sided Fisher's exact test).
We next compared CTMP hypermethylation and/or reduced mRNA expression with previously published data (11) on PTEN and EGFR gene alterations in the 93 glioblastomas (Fig. 2,  B) . PTEN mutations were present in similar fractions of glioblastomas with and without reduced CTMP mRNA expression (27% versus 30%; P ϭ .599, chi-square test) and with and without CTMP hypermethylation (32% versus 27%; P ϭ .749, chi-square test). Similarly, five of six cell lines with CTMP hypermethylation (A172, U138MG, U178MG, U251MG, and U373MG) and two of three cell lines without CTMP hypermethylation (T98G and U118MG) carry PTEN mutations (12, 13) . Thus, we conclude that there is no association between PTEN inactivation and CTMP aberrations in glioblastomas. We also detected no relationship between CTMP hypermethylation and EGFR gene amplification ( Fig. 2, B ; P ϭ .505, chisquare test).
To investigate the Akt activation status in primary glioblastomas, we performed western blot analyses of 15 selected tumors, including samples with CTMP hypermethylation (GB103D), PTEN mutations (GB47D and GB96D), EGFR amplification (GB98D, GB131D, GB139D, and GB140D), and alteration in none (GB60D, GB105D, GB147D, GB181D, and GS11D) or in any two or three of these genes (GB101D, GB191D, and GS3D). Relative to Akt protein levels in non-neoplastic brain tissue, all tumors showed increased levels of serine 473-phosphorylated Akt protein (Fig. 1, E ). In agreement with previous studies (4, 6) , these findings indicate that Akt is activated in the majority of glioblastomas, including those tumors with alterations in expression or function of PTEN, CTMP, and/or EGFR.
We found that CTMP mRNA levels were reduced by 50% or more compared Fig. 2. A) Methylation patterns in the 5Ј-CpG island of the carboxyl-terminal modulator protein (CTMP) in nine glioma cell lines, 15 primary glioblastomas, and four non-neoplastic brain samples (NB1-NB4). Methylation at each of the 67 investigated CpG sites located between nucleotides Ϫ525 and 233 was determined by amplification of three overlapping fragments (top) from sodium bisulfite-treated DNA. The fragments were cloned, and at least five clones from each fragment were sequenced per original sample. The results are represented as quintiles of methylation in a gray-scale pattern indicating the percentage of clones with methylation at each CpG site (i.e., the percentage of methylated clones among the totally sequenced clones). CTMP expression (CTMP expr.) was determined by real-time reverse transcription-polymerase chain reaction (PCR). Hatched boxes ϭ CTMP mRNA levels reduced by at least 50% relative to levels in non-neoplastic brain samples; white boxes ϭ CTMP mRNA levels of 60% or more relative to levels in nonneoplastic brain. The location of exon 1 and the start codon (ATG) are indicated.
B)
Comparison between CTMP hypermethylation, phosphatase and tensin homolog deleted on chromosome 10 (PTEN) gene mutations, and epidermal growth factor receptor (EGFR) amplification in 93 glioblastomas (case numbers listed to the left of each panel). CTMP methylation was assessed by PCR analysis of eight fragments from the CTMP 5Ј-CpG island that contained HpaII restriction sites (1) (2) (3) (4) (5) (6) (7) (8) . Black boxes ϭ signal intensity for HpaII-digested template equal to that for undigested template (complete methylation); gray boxes ϭ weaker signal intensity for HpaII-digested template than that for undigested template (partial methylation); white boxes ϭ no signal for HpaIIdigested template (no methylation). Tumors with PTEN mutation or EGFR amplification are indicated by horizontally and vertically striped boxes, respectively (data are from (11) ]. Reduced CTMP transcript levels (hatched boxes) are closely associated with CTMP hypermethylation. PTEN mutation and EGFR amplification are not associated with CTMP hypermethylation.
with non-neoplastic brain tissue in 40% of primary glioblastomas and in 67% of glioma cell lines. Our findings suggest reduced CTMP expression as a novel molecular mechanism involved in the pathogenesis of glioblastomas. Reduced CTMP expression was closely associated with CTMP 5Ј-CpG island hypermethylation and could be restored by 5-aza-2Ј-deoxycytidine and trichostatin A treatment. These findings suggest a role for epigenetic DNA modification in the regulation of CTMP promoter activity. We found that CTMP gene promoter hypermethylation and reduced mRNA expression in glioblastomas are not associated with PTEN mutations and EGFR amplification. Whether our findings regarding CTMP expression and regulation are unique to glioblastomas or are also relevant to other tumors remains to be determined.
